Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible enterococcus faecium infections

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 515-516

  Kelesidis, Theodoros ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Daptomycin; Enterococci; Resistance

Indexed keywords

CARDIOLIPIN; DAPTOMYCIN; METRONIDAZOLE;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIUM ISOLATION; CARBOHYDRATE METABOLISM; CASE CONTROL STUDY; DRUG EFFICACY; DRUG MECHANISM; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; GENE EXPRESSION; HUMAN; IN VIVO STUDY; INFECTION RISK; INTESTINE FLORA; LACTOSE OPERON; LETTER; PHOSPHOLIPID METABOLISM; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; VANCOMYCIN;

EID: 84855860121     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr465     Document Type: Letter

References (12)

1. Kelesidis T, Humphries R, Uslan DZ et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52: 228-34.
2. King ST, Usery JB, Holloway K et al. Successful therapy of treatmentemergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. J Antimicrob Chemother 2011; 66: 2673-5.
3. Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365: 892-900.
4. Palmer KL, Daniel A, Hardy C et al. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011; 55: 3345-56.
5. O'Brien TF. What has kept the antibiotic miracle alive? N Engl J Med 2011; 365: 953-5.
6. Scott KP. The role of conjugative transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract. Cell Mol Life Sci 2002; 59: 2071-82.
7. Garnier F, Taourit S, Glaser P et al. Characterization of transposon Tn1549, conferring VanB-type resistance in Enterococcus spp. Microbiology 2000; 146: 1481-9.
8. Silber P, Borie RP, Mikowski EJ et al. Phospholipid biosynthesis in some anaerobic bacteria. J Bacteriol 1981; 147: 57-61.
9. Lapierre L, Mollet B, Germond JE. Regulation and adaptive evolution of lactose operon expression in Lactobacillus delbrueckii. J Bacteriol 2002; 184: 928-35.
10. Bhalla A, Pultz NJ, Ray AJ et al. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 2003; 24: 644-9.
11. Judge T, Pogue J, Marchaim D et al. Risk factors for daptomycinnonsusceptible vancomycin-resistant enterococci: a case-case control study. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract 192. American Society for Microbiology, Washington, DC, USA.
12. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 Gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003; 47: 337-41.